Filing Details
- Accession Number:
- 0001209191-17-055918
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-04 17:01:00
- Reporting Period:
- 2017-10-02
- Accepted Time:
- 2017-10-04 17:01:00
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-10-02 | 3,437 | $73.51 | 117,861 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-10-02 | 1,394 | $151.04 | 116,467 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-02 | 1,443 | $151.82 | 115,024 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2017-10-02 | 600 | $152.62 | 114,424 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2017-10-02 | 3,437 | $0.00 | 3,437 | $73.51 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,438 | 2024-01-01 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $151.04 (range $150.37 to $151.36).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $151.82 (range $151.47 to $152.18).
- Open market sales reported on this line occurred at a weighted average price of $152.62 (range $152.54 to $152.70).
- The option vests in 16 quarterly installments from 1/2/2014.
Billionaire Hedge Funds
